Role of transient receptor potential vanilloid 4 activation in indomethacin-induced intestinal damage

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 1, 2014, Pages

  Yamawaki, Hidemoto ^a   Mihara, Hiroshi ^a   Suzuki, Nobuhiro ^a   Nishizono, Hirofumi ^a   Uchida, Kunitoshi ^b   Watanabe, Shiro ^a   Tominaga, Makoto ^b   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

Intestine; Nonsteroidal anti inflammatory drugs

Indexed keywords

ARACHIDONIC ACID; INDOMETACIN; N (METHYLSULFONYL) 2 (2 PROPYNYLOXY)BENZENEHEXANAMIDE; OXYGENASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 4;

ANIMAL EXPERIMENT; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; GENE SILENCING; IMMUNOCHEMISTRY; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

INTESTINE; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS;

ADULT; AGED; ANIMALS; ARACHIDONIC ACID; CALCIUM SIGNALING; CELL LINE; DISEASE MODELS, ANIMAL; ELECTRIC IMPEDANCE; HUMANS; INDOMETHACIN; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PEPTIC ULCER; PERMEABILITY; RATS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TRPV CATION CHANNELS;

EID: 84903641691     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00105.2013     Document Type: Article

References (45)

1. Arakawa T, Watanabe T, Tanigawa T, Tominaga K, Otani K, Nadatani Y, Fujiwara Y. Small intestinal injury caused by nsaids/aspirin: finding new from old. Curr Med Chem 19: 77-81, 2012.
2. Bardhan KD, Bjarnason I, Scott DL, Griffin WM, Fenn GC, Shield MJ, Morant SV. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 32: 990-995, 1993.
3. Benfenati V, Caprini M, Dovizio M, Mylonakou MN, Ferroni S, Ottersen OP, Amiry-Moghaddam M. An aquaporin-4/transient receptor potential vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. Proc Natl Acad Sci USA 108: 2563-2568, 2011.
4. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Abstract). J Am Coll Cardiol 52: 1502, 2008.
5. Chen YH, Lu Q, Goodenough DA, Jeansonne B. Nonreceptor tyrosine kinase c-Yes interacts with occludin during tight junction formation in canine kidney epithelial cells. Mol Biol Cell 13: 1227-1237, 2002.
6. D'Aldebert E, Cenac N, Rousset P, Martin L, Rolland C, Chapman K, Selves J, Alric L, Vinel JP, Vergnolle N. Transient receptor potential vanilloid 4 activated inflammatory signals by intestinal epithelial cells and colitis in mice. Gastroenterology 140: 275-285, 2011.
7. Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP, Hayward NJ, McNamara CR, Xue F, Moran MM, Strassmaier T, Uykal E, Owsianik G, Vennekens R, De Ridder D, Nilius B, Fanger CM, Voets T. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA 107: 19084-19089, 2010.
8. Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: from structure to disease. Prog Biophys Mol Biol 103: 2-17, 2010.
9. Fichna J, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Małecka-Panas E, Janecka A, Krajewska WM, Storr MA. Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterol Motil 24: e557-e560, 2012.
10. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 69: 1339-1346, 2009.
11. Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 46: 57-64, 2011.
12. Fulton D, Falck JR, McGiff JC, Carroll MA, Quilley J. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J Lipid Res 39: 1713-1721, 1998.
13. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136: 202-210, 2008.
14. Gevaert T, Vriens J, Segal A, Everaerts W, Roskams T, Talavera K, Owsianik G, Liedtke W, Daelemans D, Dewachter I, Van Leuven F, Voets T, De Ridder D, Nilius B. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 117: 3453-3462, 2007.
15. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users (Abstract). Clin Gastroenterol Hepatol 3: 55, 2005.
16. Hayashi Y, Yamamoto H, Kita H, Sunada K, Sato H, Yano T, Iwamoto M, Sekine Y, Miyata T, Kuno A, Iwaki T, Kawamura Y, Ajibe H, Ido K, Sugano K. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy (Abstract). World J Gastroenterol 11: 4861, 2005.
17. Jin M, Wu Z, Chen L, Jaimes J, Collins D, Walters ET, O'Neil RG. Determinants of TRPV4 activity following selective activation by small molecule agonist GSK1016790A. PLoS One 6: e16713, 2011.
18. Kida N, Sokabe T, Kashio M, Haruna K, Mizuno Y, Suga Y, Nishikawa K, Kanamaru A, Hongo M, Oba A, Tominaga M. Importance of transient receptor potential vanilloid 4 (TRPV4) in epidermal barrier function in human skin keratinocytes. Pflugers Arch 463: 715-725, 2012.
19. Mihara H, Boudaka A, Sugiyama T, Moriyama Y, Tominaga M. Transient receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in mouse oesophageal keratinocytes. J Physiol 589: 3471-3482, 2011.
20. Mihara H, Boudaka A, Shibasaki K, Yamanaka A, Sugiyama T, Tominaga M. Involvement of TRPV2 activation in intestinal movement through nitric oxide production in mice. J Neurosci 30: 16536-16544, 2010.
21. Mion F, Cuber JC, Minaire Y, Chayvialle JA. Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor. Gut 35: 490-495, 1994.
22. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 16: 1112-1119, 2001.
23. Mizuno A, Matsumoto N, Imai M, Suzuki M. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol 285: C96-C101, 2003.
24. Moreland KT, Procknow JD, Sprague RS, Iverson JL, Lonigro AJ, Stephenson AH. Cyclooxygenase (COX)-1 and COX-2 participate in 5,6-epoxyeicosatrienoic acid-induced contraction of rabbit intralobar pulmonary arteries. J Pharmacol Exp Ther 321: 446-454, 2007.
25. Naoi K, Kogure S, Saito M, Hamazaki T, Watanabe S. Differential effects of selective cyclooxygenase (COX)-1 and COX-2 inhibitors on anorexic response and prostaglandin generation in various tissues induced by zymosan. Biol Pharm Bull 29: 1319-1324, 2006.
26. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol 17: 4647-4653, 2011.
27. Quaroni A, Wands J, Trelstad RL, Isselbacher KJ. Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol 80: 248-265, 1979.
28. Reiter B, Kraft R, Günzel D. TRPV4-mediated regulation of epithelial permeability. FASEB J 20: 1802-1812, 2006.
29. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14: 333-341, 1997.
30. Sokabe T, Fukumi-Tominaga T, Yonemura S, Mizuno A, Tominaga M. The TRPV4 channel contributes to intercellular junction formation in keratinocytes. J Biol Chem 285: 18749-18758, 2010.
31. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 278: 22664-22668, 2003.
32. Tabuchi K, Suzuki M, Mizuno A, Hara A. Hearing impairment in TRPV4 knockout mice. Neurosci Lett 382: 304-308, 2005.
33. Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 411: 459-466, 2010.
34. Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med 4: 148-159, 2012.
35. Vincent F, Acevedo A, Nguyen MT, Dourado M, DeFalco J, Gustafson A, Spiro P, Emerling DE, Kelly MG, Duncton MA. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun 389: 490-494, 2009.
36. Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, Nilius B. Modulation of the Ca(2) permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97: 908-915, 2005.
37. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 19: 1861-1876, 2013.
38. Wallace JL, McKnight W, Miyasaka M, Tamatani T, Paulson J, Anderson DC, Granger DN, Kubes P. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 265: G993-G998, 1993.
39. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322, 2011.
40. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434-438, 2003.
41. Watanabe H, Vriens J, Suh SH, Benham CD, Droogmans G, Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells. J Biol Chem 277: 47044-47051, 2002.
42. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: 181-187, 2008.
43. Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulpizio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, Lashinger ES, Figueroa DJ, Marquis R, Xu X. Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J Pharmacol Exp Ther 326: 443-452, 2008.
44. Yoshida T, Inoue R, Morii T, Takahashi N, Yamamoto S, Hara Y, Tominaga M, Shimizu S, Sato Y, Mori Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat Chem Biol 2: 596-607, 2006.
45. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27: 1931-1940, 2007.